Skip to content
Home
About us
Co-founders
Our Team
Our Product Pipeline
Our Technology
Scientific Advisors
Investors
Science
AMD and Eyecyte-RPE
TM
Retinitis pigmentosa and Eyecyte-PRP
TM
AAV – mediated gene therapy
Publications
Resources
News and Media
Recognition
Collaborations
Research Alliance
Careers
Contact Us
Home
About us
Co-founders
Our Team
Our Product Pipeline
Our Technology
Scientific Advisors
Investors
Science
AMD and Eyecyte-RPE
TM
Retinitis pigmentosa and Eyecyte-PRP
TM
AAV – mediated gene therapy
Publications
Resources
News and Media
Recognition
Collaborations
Research Alliance
Careers
Contact Us
Eyestem Announces completion of Phase one of its RPE cell therapy with promising efficacy and safety outcomes
Home
update
Eyestem Announces completion of Phase one of its RPE cell therapy with promising efficacy and safety outcomes
Post Author:
eyetem@admin
Post navigation
Previous Post
Eyestem’s Eyecyte-RPE™ Trial Shows Vision Rescue for Geographic Atrophy Patients
